Tamrazi Anobel, Sundaresan Srividya, Gulati Aishwarya, Tan Frederick J, Wadhwa Vibhor, Bartlett Bjarne R, Diaz Luis A Jr
Division of Vascular and Interventional Radiology, Palo Alto Medical Foundation, Redwood City, CA, United States.
Department of Clinical Research, Dignity Health, Sequoia Hospital, Redwood City, CA, United States.
Front Oncol. 2023 Mar 17;13:916196. doi: 10.3389/fonc.2023.916196. eCollection 2023.
Circulating tumor-derived biomarkers can potentially impact cancer management throughout the continuum of care. This small exploratory study aimed to assess the relative levels of such biomarkers in the tumor-draining vascular beds in patients with solid tumors compared to levels in their peripheral veins.
Using an endovascular image-guided approach, we obtained blood samples from peripheral veins and other vascular compartments-including the most proximal venous drainage from solid tumors-from a set of nine oncology patients with various primary and metastatic malignancies. We then interrogated these samples for a panel of oncological biomarkers, including circulating tumor cells (CTCs), exosome-derived microRNAs (miRNAs), circulating tumor DNA (ctDNA) mutations, and certain cancer-related proteins/biochemical markers.
We found substantially higher levels of CTCs, certain miRNAs, and specific ctDNA mutations in samples from vascular beds closer to the tumor compared with those from peripheral veins and also noted that some of these signals were altered by treatment procedures.
Our results indicate that tumor-proximal venous samples are highly enriched for some oncological biomarkers and may allow for more robust molecular analysis than peripheral vein samples.
循环肿瘤衍生生物标志物可能会在整个连续护理过程中对癌症管理产生影响。这项小型探索性研究旨在评估实体瘤患者肿瘤引流血管床中此类生物标志物的相对水平,并与外周静脉中的水平进行比较。
采用血管内图像引导方法,我们从一组9名患有各种原发性和转移性恶性肿瘤的肿瘤患者的外周静脉和其他血管腔室(包括实体瘤最近端的静脉引流)采集血样。然后,我们对这些样本进行了一组肿瘤生物标志物检测,包括循环肿瘤细胞(CTC)、外泌体衍生的微小RNA(miRNA)、循环肿瘤DNA(ctDNA)突变以及某些癌症相关蛋白/生化标志物。
我们发现,与外周静脉样本相比,来自更接近肿瘤的血管床样本中的CTC、某些miRNA和特定ctDNA突变水平显著更高,并且还注意到其中一些信号会因治疗程序而改变。
我们的结果表明,肿瘤近端静脉样本中某些肿瘤生物标志物高度富集,与外周静脉样本相比,可能允许进行更强大的分子分析。